Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.39
18.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Anhui Huaren Health Pharmaceutical Co Ltd
Cost of Revenue
Anhui Huaren Health Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Cost of Revenue
-¥2.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Cost of Revenue
-¥17B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Cost of Revenue
-¥15.1B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Cost of Revenue
-¥14.7B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Cost of Revenue
-¥6.6B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Cost of Revenue
-¥12.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-18%
|
|
Anhui Huaren Health Pharmaceutical Co Ltd
Glance View
Anhui Huaren Health Pharmaceutical Co., Ltd. engages in pharmaceutical distribution. The company is headquartered in Hefei, Anhui and currently employs 5,785 full-time employees. The company went IPO on 2023-03-01. The pharmaceutical retail business is mainly engaged in the sales of medicines, health food and medical equipment, as well as the diagnosis and treatment of common diseases. The agency business mainly promotes and sells to downstream pharmaceutical retail enterprises. The terminal centralized procurement business mainly provides one-stop distribution services for individual pharmacies and small chain retail terminals.
See Also
What is Anhui Huaren Health Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-2.6B
CNY
Based on the financial report for Dec 31, 2023, Anhui Huaren Health Pharmaceutical Co Ltd's Cost of Revenue amounts to -2.6B CNY.
What is Anhui Huaren Health Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-29%
Over the last year, the Cost of Revenue growth was -20%. The average annual Cost of Revenue growth rates for Anhui Huaren Health Pharmaceutical Co Ltd have been -29% over the past three years .
You don't have any saved screeners yet
